Two Clinical Stage Products Lead The Way In A Promising Pipeline – Small Cap IR

According to the World Health Organization, over 14 million new cases of cancer are reported each year and cancer cases are expected to surge 57% worldwide over the next 20 years. The fastest growing hospital treatment in the United States to treat this disease is Hematopoietic Stem Cell Transplantation; the transplantation of multipotent hematopoietic stem cells derived from bone marrow, peripheral blood, or umbilical cord blood.

Actinium Pharmaceuticals, Inc. is biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company’s products are based on patented technology co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) for combining monoclonal antibodies (mAb) for targeting specific types of cells with alpha emitting radioisotopes. The company has developed drugs for treating leukemia, metastatic colorectal and prostate cancers, antiangiogenesis (prevention of blood supply to and growth of many solid cancers), and bone marrow ablation (a treatment for leukemias, lymphomas and multiple myeloma).

An analyst report on ATNM that includes a company overview, market and competition breakdown, recent events, outlook, valuation, analyst summary and recommendation can be viewed by using the following link at no cost.

For more information, visit http://bit.ly/_ATNM_AnalystReport.

About Small Cap IR
We make the connection between sophisticated investors and high quality public companies. An issuer of reports written by chartered financial analysts (CFA’s) who provide a straightforward assessment of the profiled company and have pledged to remain free of influence when writing research reports. They include stocks traded in the NYSE, NASDAQ, and OTCBB exchanges.